Novel Intravaginal Drug Delivery System Based on Molecularly PEGylated Lipid Matrices for Improved Antifungal Activity of Miconazole Nitrate

Table 2

Formulation composition of miconazole nitrate-loaded SLMs.

Batch code	Lipid; matrix; (%w/w)	Miconazole; nitrate; (%w/w)	Tween® 80; (%w/w)	Soluplus®; (%w/w)	Sorbic acid; (%w/w)	Distilled water q.s. to 100 %w/w
AM1	10.0	1.0	1.0	4.0	0.1	100.0
BM1	10.0	1.0	1.0	4.0	0.1	100.0
CM1	10.0	1.0	1.0	4.0	0.1	100.0
DM1	10.0	1.0	1.0	4.0	0.1	100.0
AM2	10.0	2.0	1.0	4.0	0.1	100.0
BM2	10.0	2.0	1.0	4.0	0.1	100.0
CM2	10.0	2.0	1.0	4.0	0.1	100.0
DM2	10.0	2.0	1.0	4.0	0.1	100.0
AM3	10.0	3.0	1.0	4.0	0.1	100.0
BM3	10.0	3.0	1.0	4.0	0.1	100.0
CM3	10.0	3.0	1.0	4.0	0.1	100.0
DM3	10.0	3.0	1.0	4.0	0.1	100.0
A0	10.0	0.0	1.0	4.0	0.1	100.0
B0	10.0	0.0	1.0	4.0	0.1	100.0
C0	10.0	0.0	1.0	4.0	0.1	100.0
D0	10.0	0.0	1.0	4.0	0.1	100.0

Key: batches (A₀, AM₁–AM₃) are non-PEGylated SLMs; batches B, C, and D are PEGylated SLMs containing increasing concentrations (1.0, 2.0, and 4.0 %w/w) of PEG 4000, respectively; A₀–D₀ are unloaded SLMs while batches AM₁–DM₁, AM₂–DM₂, and AM₃–DM₃ contain increasing concentrations (1.0, 2.0, and 3.0 %w/w) of miconazole nitrate, respectively.